A Study Of Ranpirnase(Onconase®) To Pemetrexed Plus Carboplatin In Patients With Non-Squamous Non-Small Cell Lung Cancer
The purpose of the trial is to determine the rate of improvement in objective tumor response, following the addition of ranpirnase to ongoing pemetrexed-carboplatin chemotherapy, for patients with SD or PR following 2 cycles of doublet chemotherapy.
Checked against the public recordLast updated Sep 2, 2015 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Tamir Biotechnology, Inc.
- Interventions being studied
- Drug: Ranpirnase
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Age greater than 18 years * ECOG less than 2 * Estimated survival of greater than 12 weeks Exclusion Criteria: * Prior systemic chemotherapy for locally advanced or metastatic NSCLC * Use of any investigational agent within 28 days prior to registration * Known hypersensitivity to any of the study drugs * Brain metastases or leptomeningeal disease * History of prior malignancy within the past three years
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Tower Cancer Research FoundationBeverly Hills, California
- Van Andel Research InstituteGrand Rapids, Michigan
- Sletten Cancer SpecialistsGreat Falls, Montana
- The Cancer Institute at NYU Langone Medical CenterNew York, New York
- Tri-county Hematology-Oncology Associates, IncCanton, Ohio
- Northern Utah AssociatesOgden, Utah
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 2, 2015. Always confirm current availability with the study team.